产品
编 号：F343276
分子式：C17H19Cl2N7O
分子量：408.29
分子式：C17H19Cl2N7O
分子量：408.29
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 383150-41-2
产品详情
生物活性：
JTE-013 is a potent and specific S1P2 (Sphingosine-1-Phosphate 2; EDG-5) antagonist. JTE-013 inhibits the specific binding of radiolabeled S1P to human and rat S1P2 with IC50s of 17 nM and 22 nM, respectively.
体内研究：
JTE-013 (gavage; 30 mg/kg daily for 14 consecutive days) reduces tumor size and tumor weight. Animal Model:Six-week-old female athymic NCr-nu/nu nude mice
Dosage:30 mg/kg
Administration:Gavage; daily for 14 consecutive days
Result:Reduced tumor size and tumor weight.
体外研究：
JTE-013 (50-200 μM; 1-3 days) reduces cell viability. ?JTE-013 (10-1000 nM; 30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation.?JTE-013 displays 4.2% inhibition of S1P3 and does not antagonize S1P1 at concentrations up to 10 μM.
JTE-013 is a potent and specific S1P2 (Sphingosine-1-Phosphate 2; EDG-5) antagonist. JTE-013 inhibits the specific binding of radiolabeled S1P to human and rat S1P2 with IC50s of 17 nM and 22 nM, respectively.
体内研究：
JTE-013 (gavage; 30 mg/kg daily for 14 consecutive days) reduces tumor size and tumor weight. Animal Model:Six-week-old female athymic NCr-nu/nu nude mice
Dosage:30 mg/kg
Administration:Gavage; daily for 14 consecutive days
Result:Reduced tumor size and tumor weight.
体外研究：
JTE-013 (50-200 μM; 1-3 days) reduces cell viability. ?JTE-013 (10-1000 nM; 30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation.?JTE-013 displays 4.2% inhibition of S1P3 and does not antagonize S1P1 at concentrations up to 10 μM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备